Demographic and baseline data of 79 patients with hematological cancer
| . | N = 79 . |
|---|---|
| Age, y, mean (95% CI) | 67 (63-71) |
| Male, n (%) | 30 (38) |
| BMI, kg/m2, mean (95% CI) | 27 (25-28) |
| Smoking status, n (%) | |
| Active smoker, | 4 (5) |
| Previous smoker | 28 (35) |
| Never smoked | 47 (59) |
| Platelet inhibitor and anticoagulation, n (%) | |
| Acetylsalicylic acid | 13 (16) |
| Clopidogrel | 4 (5) |
| Rivaroxaban | 4 (5) |
| Bleeding and thrombosis within previous 3 mo, n (%) | |
| Arterial thrombosis | 2 (3) |
| Venous thrombosis | 1 (1) |
| Bleeding WHO grade ≥2 | 2 (3) |
| Diagnosis, n (%) | |
| Lymphoma | 39 (49) |
| Myeloproliferative syndromes | 19 (24) |
| MM/amyloidosis | 15 (19) |
| AML/MDS | 6 (8) |
| ALL | 0 (0) |
| . | N = 79 . |
|---|---|
| Age, y, mean (95% CI) | 67 (63-71) |
| Male, n (%) | 30 (38) |
| BMI, kg/m2, mean (95% CI) | 27 (25-28) |
| Smoking status, n (%) | |
| Active smoker, | 4 (5) |
| Previous smoker | 28 (35) |
| Never smoked | 47 (59) |
| Platelet inhibitor and anticoagulation, n (%) | |
| Acetylsalicylic acid | 13 (16) |
| Clopidogrel | 4 (5) |
| Rivaroxaban | 4 (5) |
| Bleeding and thrombosis within previous 3 mo, n (%) | |
| Arterial thrombosis | 2 (3) |
| Venous thrombosis | 1 (1) |
| Bleeding WHO grade ≥2 | 2 (3) |
| Diagnosis, n (%) | |
| Lymphoma | 39 (49) |
| Myeloproliferative syndromes | 19 (24) |
| MM/amyloidosis | 15 (19) |
| AML/MDS | 6 (8) |
| ALL | 0 (0) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BMI, body mass index; CI, confidence interval; MDS, myelodysplastic syndrome; MM, multiple myeloma.